17th October 2024
NovalGen to collaborate with CRUK to progress NVG-222 into a Phase I clinical study
10th December 2023
NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting
2nd November 2023
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
8th June 2023
NovalGen announces two oral presentations at upcoming conferences
2nd May 2023
NovalGen appoints Prof. David Venables to the Board of Directors
9th January 2023
NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors
3rd November 2022
NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting
26th May 2022
NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting
17th September 2021
NovalGen announces data presentation at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia
9th June 2021
NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
20th May 2021
NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma
7th April 2021
NovalGen receives CTA approval to start a Phase 1/2 first in human study to evaluate the safety, pharmacokinetics and efficacy of NVG-111 in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
22nd February 2021
NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials
19th February 2021
NovalGen announces updates to its executive management team
6th October 2020
Novalgen licenses mAbsolve’s QumAb™ technology to improve the safety of therapeutic antibodies
